AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03463252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
Study NCT03463252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Description: GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
Study NCT02629042 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial endodontic treatment under local and/or locoregional anesthesia
Description: The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
Study NCT02629042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
Study NCT01129804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: Patients in both treatments will be taught skills to help them keep from drinking.
Study NCT01129804 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Skills Training
Description: Patients in both treatments will be taught skills to help them keep from drinking.
Study NCT03538704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is given to patients 1-1.5g/d.
Study NCT03371056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacteriological analyses on clinical samples performed with swabs
Description: Bacteriological analyses will be performed to assess the InSPIRe kit
Study NCT02347072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Study NCT02347072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI
Study NCT02347072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® Respimat® (Tiotropium Bromide)
Description: Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Study NCT04235842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: Moderate-intensity continuous exercise training performed at cycle ergometer.
Study NCT04235842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training performed at cycle ergometer.
Description: High-intensity interval training performed at cycle ergometer.
Study NCT02131116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Metacognitive Therapy
Description: Integrated Metacognitive Therapy
Study NCT02131116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual
Study NCT01660802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 μg Dexamethasone
Description: 700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
Study NCT01660802 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 700 μg Dexamethasone
Description: 700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
Study NCT01660802 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham administered in the study eye on Day 1.
Study NCT00934232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
Study NCT03809325 — intervention group
Intervention type: DRUG
Intervention: Paliperidone Palmitate 3-Month Formulation (PP3M)
Description: No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
Study NCT02774187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: administration of Sorafenib
Study NCT02774187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: administration of Sorafenib
Study NCT00794924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3
Description: one sachet per day, for 45 consecutive days
Study NCT00794924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: one sachet per day, for 45 consecutive days
Study NCT00794924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one sachet per day, for 45 consecutive days
Study NCT02718222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-partum IUD
Description: The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
Study NCT00763451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00763451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT00763451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00763451 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT00763451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT00763451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study NCT00348387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliomyelitis Vaccine inactivated
Description: 0.5 mL, Intramuscular
Study NCT00348387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)
Description: 1g dragee, oral
Study NCT01383330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megace
Description: 800mg
Study NCT01383330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-ES(A)
Description: 625mg
Study NCT01383330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW-ES(B)
Description: 625mg
Study NCT00603811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX102 [Flagellin.HuM2e]
Description: dose ranging, 2 i.m. doses given 28 days apart
Study NCT00603811 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03557606 — intervention group
Intervention type: PROCEDURE
Intervention: Alar treatment with BMC using anterior approach
Description: Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
Study NCT00727506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 once daily
Study NCT00727506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: TMZ 21/28
Study NCT00727506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 plus TMZ
Description: BIBW 2992 once daily plus TMZ 21/28 days
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, Twice Daily, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Description: Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily 24 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2a
Description: Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
Study NCT01030432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
Study NCT01035541 — intervention group
Intervention type: DEVICE
Intervention: PiCCO® Monitoring
Description: Fluid and vasopressor management according to PiCCO measruements
Study NCT02498236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Study NCT02498236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin
Study NCT01228877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Adduction, Abduction and Squat exercise three times a week for 16 weeks
Study NCT03031210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: (90 mg/kg/day) twice daily
Study NCT03031210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: (90 mg/kg/day) twice daily
Study NCT02078492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of Ketorolac
Description: Patients will receive 10 mg of Ketorolac for pain control.
Study NCT02078492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg of Ketorolac
Description: Patients will receive 15mg of Ketorolac for pain control.
Study NCT02078492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg of Ketorolac
Description: Patients will receive 30mg of Ketorolac for pain control.
Study NCT06394609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double loaded knotted suture anchor
Description: arthroscopic bankart repair by using double loaded knotted suture anchor
Study NCT06394609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double grand knot
Description: arthroscopic bankart repair by using double grand knot
Study NCT00383123 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1.
Study NCT00383123 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Subjects were administered 1 or 2 doses\* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children \< 12 months.~\*Only those subjects between the age of 6 months and \< 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 \& 1.
Study NCT03230825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
Study NCT03230825 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectant management
Description: No intervention and a follow up visit a wewk later
Study NCT00544232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa
Description: Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel
Study NCT00544232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Description: Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF
Study NCT02760901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
Study NCT02760901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
Study NCT02760901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
Study NCT02760901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline hydration 2500 ml before cisplatin therapy
Study NCT02760901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: patients with tumours already prescribed cisplatin
Study NCT02683499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic tips
Description: These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
Study NCT00455741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol infusion
Description: Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
Study NCT00455741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone infusion
Description: Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
Study NCT04699760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: 8 weeks, 2.2 G EPA/day
Study NCT04699760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03028597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Values Affirmation
Description: Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
Study NCT03028597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Values Affirmation
Description: Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
Study NCT01160627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydration
Description: Saline hydration
Study NCT01160627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine
Description: Acetylcystein tablets for 2 days
Study NCT01160627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
Study NCT01160627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Acetylcystein and Sodium Bicarbonate
Description: Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
Study NCT01821937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: faldaprevir(high dose)
Description: faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
Study NCT01821937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir(low dose)
Description: faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
Study NCT03411785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPC+ model
Description: CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
Study NCT03554031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Growth Hormone (rhGH) Injection
Description: Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
Study NCT02928731 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set 1
Description: Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
Study NCT02928731 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set 2
Description: Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
Study NCT02539316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid
Study NCT02539316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Médialipides
Study NCT00305344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Umbilical Cord Blood Transfusion
Description: Cord Blood infusion
Study NCT00305344 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cord blood
Description: Develop Cord blood vaccine
Study NCT00570908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sutent
Study NCT00570908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: concurrently
Study NCT00570908 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: Whole Brain Radiotherapy 30 Gy in 10 fractions